Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.

27 Jan 2010

Focused Ultrasound Surgery Foundation disbursed $1 million in research awards; looks forward to fund more projects in 2010

The Focused Ultrasound Surgery Foundation has disbursed nearly $1 million in research awards for work on a breakthrough medical technology and is making more project funding available in 2010.

22 Jan 2010

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

Researchers at the University of Southern California (USC) have, for the first time, identified specific genetic variations that predict clinical outcomes in patients with gastric (stomach) cancer.

22 Jan 2010

AKD Global announces new class of cancer treatments in development

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

22 Jan 2010

New learning centre dedicated to train CT health care specialists established

The Michener Institute for Applied Health Sciences and GE Healthcare Canada today announced the establishment of a new learning centre dedicated to training both the current and next generation of CT health care specialists.

22 Jan 2010

Research reveals gene activation is linked to most aggressive type of brain cancer

Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.

18 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

In a first-ever initiative, renowned health-care providers identify and describe how cancer treatment-related toxicities have a negative effect on quality of life from the perspective of patients and survivors.

7 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD).

6 Jan 2010

RFA reduces pain in bone metastases patients

Image-guided radiofrequency ablation (RFA), a minimally invasive cancer treatment which can be performed in the outpatient setting, significantly reduced the level of pain experienced by cancer patients with bone (osseous) metastases, limiting the need for strong narcotic pain management, and supporting improved patient frame of mind, according to results of an American College of Radiology Imaging Network (ACRIN) study published online in the journal Cancer.

5 Jan 2010

FDA approves minimally invasive procedure for treating benign and malignant tumors

A minimally invasive surgical approach developed by head and neck surgeons at the University of Pennsylvania School of Medicine has been cleared by the U.S. Food and Drug Administration (FDA). The

5 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Nukepills.com delivers 5.4 million doses of Potassium Iodide to protect people from nuclear radiation

For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.

31 Dec 2009

CPF reports success in advocacy, research support and awareness of PF

The Coalition for Pulmonary Fibrosis (CPF) calls 2009 a year of success in advocacy, research support and awareness, even in a year plagued by the economic recession. PF is a fatal disease that has no known cause, no FDA-approved treatment, and no cure.

30 Dec 2009

Elekta Crawley receives the World Class Manufacturer of the Year 2009 award

Elekta, the world-leading manufacturer of treatment solutions for cancer and brain disorders, has been awarded the prestigious World Class Manufacturing award by The Manufacturer magazine. The award was given in recognition of the quality work produced each year by Elekta manufacturing staff.

From Elekta 29 Dec 2009

Radiation Therapy News and Research

Further Reading

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

Focused Ultrasound Surgery Foundation disbursed $1 million in research awards; looks forward to fund more projects in 2010

Researchers discover genetic variations that predict clinical outcomes in patients with stomach cancer

AKD Global announces new class of cancer treatments in development

New learning centre dedicated to train CT health care specialists established

Research reveals gene activation is linked to most aggressive type of brain cancer

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

CEL-SCI completes validation of its GMP manufacturing facility

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

U.S. market for urological devices to reach over $5.4 billion in 2016

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

RFA reduces pain in bone metastases patients

FDA approves minimally invasive procedure for treating benign and malignant tumors

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Nukepills.com delivers 5.4 million doses of Potassium Iodide to protect people from nuclear radiation

CPF reports success in advocacy, research support and awareness of PF

Elekta Crawley receives the World Class Manufacturer of the Year 2009 award

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News